Shots:
- Novo Nordisk has reported P-III (FRONTIER4) extension study data assessing Mim8 (denecimig, SC) prophylaxis in paediatric & adult pts with hemophilia A, with or without inhibitors, across a range of dosing frequencies incl. QM, Q2W, & QW
- Interim data (n=426) showed Mim8’s safety was consistent with prior studies, while efficacy EPs demonstrated low mean ABRs (0.75 in adults/adolescents; 0.37 in children) across dosing regimens & inhibitor status, with ~71% of adults/adolescents & ~89% of children experiencing zero treated bleeds
- PROs showed improved joint pain (JPRS) in pts (≥12yrs.) & reduced treatment burden (Hemo-TEM) for pts (≥1yrs); Across all groups & dosing regimens, 94.1% of 185 pts rated the pen-injector easy to use & 89.7% found it quick to prepare & inject
Ref: PRnewswire | Image: Novo Nordisk | Press Release
Related News: Novo Nordisk Reports New STEP UP Trial Analyses on Wegovy 7.2mg for Weight Loss
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
